The Royal Lancaster Infirmary
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Birtle, Alison
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

Recruiting
N/A
170
Europe
Royal Marsden NHS Foundation Trust, Janssen, LP
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
04/27
04/27

Download Options